Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer

被引：0
|
作者：
John Thoms
Jayant S. Goda
Alexender R. Zlotta
Neil E. Fleshner
Theodorus H. van der Kwast
Stéphane Supiot
Padraig Warde
Robert G. Bristow
机构：
[1] Radiation Medicine Program,Division of Urology, Department of Surgical Oncology
[2] Princess Margaret Hospital,Department of Pathology
[3] University Health Network,Department of Radiation Oncology
[4] Princess Margaret Hospital,Department of Radiation Oncology
[5] University Health Network,undefined
[6] Princess Margaret Hospital,undefined
[7] University Health Network,undefined
[8] Tata Memorial Center,undefined
[9] Center René Gauducheau,undefined
来源：
Nature Reviews Clinical Oncology | 2011年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Men with locally advanced or high-risk prostate cancer may benefit from combined modality strategies. This Review discusses the approaches and rational for preoperative and intraoperative radiotherapy and compares them with the utility of postoperative radiotherapy. The urgent need for novel biomarkers for selection purposes is highlighted.
引用
收藏
页码：107 / 113
页数：6
相关论文
共 50 条
  • [1] Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer
    Thoms, John
    Goda, Jayant S.
    Zlotta, Alexendre R.
    Fleshner, Neil E.
    van der Kwast, Theodorus H.
    Supiot, St Phane
    Warde, Padraig
    Bristow, Robert G.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (02) : 107 - 113
  • [2] Neoadjuvant radiotherapy for locally advanced and high-risk breast cancer
    Chidley, Phoebe
    Foroudi, Farshad
    Tacey, Mark
    Khor, Richard
    Yeh, Janice
    Bevington, Elaine
    Hyett, Anthony
    Loh, Su Wen
    Chew, Grace
    McCracken, James
    Neoh, Derek
    Yeo, Belinda
    Baker, Caroline
    Jassal, Sunil
    Law, Michael
    Zantuck, Natalie
    Cokelek, Margaret
    Guerrieri, Mario
    Brown, Belinda
    Stoney, David
    Ng, Michael
    Chao, Michael
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2021, 65 (03) : 345 - 353
  • [3] Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer
    Hussain, M
    Smith, DC
    El-Rayes, BF
    Du, W
    Vaishampayan, U
    Fontana, J
    Sakr, W
    Wood, D
    UROLOGY, 2003, 61 (04) : 774 - 780
  • [4] Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments
    H Payne
    M Mason
    British Journal of Cancer, 2011, 105 : 1628 - 1634
  • [5] Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments
    Payne, H.
    Mason, M.
    BRITISH JOURNAL OF CANCER, 2011, 105 (11) : 1628 - 1634
  • [6] Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer
    Perez, Bradford A.
    Koontz, Bridget F.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (05) : 226 - 234
  • [7] What is appropriate neoadjuvant/adjuvant androgen deprivation for high-risk/locally advanced prostate cancer?
    Namiki, Mikio
    Konaka, Hiroyuki
    ASIAN JOURNAL OF ANDROLOGY, 2011, 13 (04) : 624 - 625
  • [8] Treatment strategies for high-risk locally advanced prostate cancer
    Seth A. Rosenthal
    Howard M. Sandler
    Nature Reviews Urology, 2010, 7 : 31 - 38
  • [9] Management of high-risk populations with locally advanced prostate cancer
    Khan, MA
    Partin, AW
    ONCOLOGIST, 2003, 8 (03): : 259 - 269
  • [10] Multimodal treatment of high-risk and locally advanced prostate cancer
    Preisser, Felix
    Tilki, Derya
    UROLOGIE, 2022, 61 (12): : 1341 - 1344
12345